Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tumor uptake of 89Zr-ofatumumab and 89Zr-rituximab in DLBCL
2012-001597-29Phase 2Terminated
- Sponsor
- VU University Medical Center
- Start
- May 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of rituximab and ofatumumab in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by VU University Medical Center. Primary endpoint: Detection of 89Zr-ofatumumab and 89Zr-rituximab in DLBCL tumor lesions. Started May 2012; status: terminated.
02
Drugs
rituximabofatumumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2012-001597-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001597-29.